Changshan Pharmaceuticals: Enoxaparin Sodium Injection Obtains Drug Registration Certificate in Tajikistan.

Changshan Pharmaceutical announced that the company's drug Enoxaparin Sodium Injection has recently obtained a drug registration certificate issued by the Tajikistan drug regulatory authority. The specifications of this drug are 0.4mL and 0.6mL, with a validity period of 5 years, used for preventing venous thrombosis, etc. This approval will have a positive impact on the company's expansion into overseas markets. However, currently, overseas sales of heparin preparations account for a relatively low proportion of the company's revenue, and drug exports are easily affected by factors such as policies, channels, and exchange rates. Investors are reminded to pay attention to the risks.